-
Sales: SEK871 million, a decrease of 7% in SEK, impacted by minus 8% due to currency.
-
Organic Growth: 3% in local currencies, excluding discontinued business.
-
Gross Margin: 58%, decreased due to currency impact.
-
EBITDA: SEK243 million, with an EBITDA margin of 27.8%.
-
Operating Cash Flow: SEK151 million for the quarter.
-
Earnings Per Share (EPS): SEK0.74.
-
Americas Region Growth: 5% organic growth in local currency.
-
EMEA Region Growth: 17% growth in Consumables in local currencies, excluding discontinued business.
-
APAC Region Growth: Flat organic growth in local currencies.
-
First Half Year Sales: SEK1.7 billion, a decrease of 4% in SEK.
-
First Half Year EBITDA: SEK500 million.
-
Net Income: SEK198 million for the first half year.
-
Equity Ratio: 78.8%.
-
Net Debt to EBITDA: 0.8x.
Release Date: July 17, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
-
Vitrolife AB (VTRLY) achieved a 9% organic growth in its Consumables business, outperforming the market and gaining share from competitors.
-
The Americas region delivered a 5% organic growth in local currency despite challenging market conditions due to the IVF executive order.
-
Vitrolife AB (VTRLY) became the lead investor in AutoIVF, advancing its strategy to create an end-to-end IVF platform.
-
The EMEA region showed strong performance with a 17% growth in Consumables, excluding discontinued business, indicating significant market share gains.
-
The company reported a strong balance sheet with an equity ratio of 78.8% and a net debt to EBITDA ratio of 0.8x.
-
Sales decreased by 7% in SEK, heavily impacted by an 8% negative currency effect.
-
Gross margin decreased to 58%, affected by currency fluctuations and increased supply chain costs.
-
EBITDA decreased to SEK243 million, with a margin of 27.8%, impacted by currency and increased US sales and marketing investments.
-
Operating cash flow dropped to SEK151 million, and earnings per share fell to SEK0.74.
-
The APAC region experienced flat organic growth, with market weakness in China and delayed capital purchases affecting performance.
Q: What is your impression of the underlying growth in EMEA and Americas, and what drives your market share gains in EMEA Consumables and Americas Genetics? A: Cycles are down in the US, but our Consumables and Genetics performance in North America is strong due to share gains. In EMEA, cycles are positive, but our consumables growth is significantly above cycle growth, driven by share gains across the portfolio, including media, disposable devices, pipettes, and needles.
